SCHEMBL6019671

SCHEMBL6019671

Cn1c(CNCCC[C@H](NC(=O)c2ccc(CNCc3ccccn3)cc2)C(=O)O)nc2ccccc21.NCc1cccc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.49
HDAC1 Q13547 3/20 0.40
HDAC6 Q9UBN7 2/20 0.40
FOLH1 Q04609 1/20 0.39
CASR P41180 1/20 0.37
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
PGGT1B P53609 1/20 0.35
GAA P10253 1/20 0.34
MAPK14 Q16539 1/20 0.34
DHFR P00374 2/20 0.33
TYMS P04818 1/20 0.33
KLK1 P06870 1/20 0.33
KLK5 Q9Y337 1/20 0.33
MAPT P10636 1/20 0.33
FPGS Q05932 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018262 0.90 CXCR4 (0.57) CXCR4HDAC1FOLH1CASRFNTA
SCHEMBL6018129 0.89 CXCR4 (0.51) CXCR4HDAC1FOLH1CASRFNTA
SCHEMBL6690573 0.88 HDAC1 (0.40) CXCR4HDAC1HDAC6FOLH1CASR
SCHEMBL6018497 0.87 CXCR4 (0.52) CXCR4HDAC1HDAC6FOLH1CASR
SCHEMBL6018574 0.86 CXCR4 (0.51) CXCR4HDAC1FOLH1CASRFNTA
SCHEMBL6018567 0.85 CXCR4 (0.54) CXCR4HDAC1FOLH1CASRFNTA
SCHEMBL6018843 0.85 CXCR4 (0.51) CXCR4HDAC1FOLH1CASRFNTA
SCHEMBL6018749 0.84 CXCR4 (0.51) CXCR4FOLH1CASRFNTAFNTB
SCHEMBL6685578 0.84 FOLH1 (0.41) HDAC1HDAC6FOLH1CASRGAA
SCHEMBL6018854 0.84 CXCR4 (0.51) CXCR4FOLH1CASRFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098215-B2 Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2006-08-29 US disclosed
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound KUREHA CORPORATION (JP) 2004-08-12 US disclosed
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same KUREHA CORPORATION (JP) 2004-05-13 US disclosed
EP-1389460-A1 CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND Kureha Chemical Industry Co., Ltd. (JP) 2004-02-18 EP disclosed
EP-1273571-A1 NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME Kureha Chemical Industry Co., Ltd. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same NSUN2, ZC3HAV1L, PNP CXCR4 2185/4885HDAC1 651/4885HDAC6 3064/4885
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound CXCR4, CXCR1, CXCR2 CXCR4 1/4885HDAC1 1092/4885HDAC6 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.